Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of carfilzomib weekly 20/56mg/m² plus lenalidomide and dexamethasone regimen in patients with early relapsed refractory multiple myeloma (RRMM)

Trial Profile

Efficacy and safety of carfilzomib weekly 20/56mg/m² plus lenalidomide and dexamethasone regimen in patients with early relapsed refractory multiple myeloma (RRMM)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jun 2019 Results of long-term exposure data on KRd weekly given until progression presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top